C21 BioVentures 2009 Presenter Profiles Monday April 6, 2009, 11:04 am EDT Buzz up! Print NAPA, Calif.--(BUSINESS WIRE)--C21 BioVentures 2009 takes place April 7-9 2009 at the Meritage Resort in Napa, California.
Business Wire is the official news wire for C21 BioVentures 2009. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.
Listed below are the C21 BioVentures 2009 presenter profiles.
Company: Biotecnol Pharmaceuticals Inc Investor Relations Contact: Dr. Pedro de Noronha Pissarra Investor Relations Contact Phone: pnp@biotecnol.com Web: www.biotecnol.com Date of Presentation: Thursday, April 09, 2009
Biotecnol Pharmaceuticals, Inc is a fully owned subsidiary of Biotecnol SA, Portugal. Biotecnol is developing novel immunotherapeutic products primarily in the oncology field. It has an integrated capability for discovery and development of novel multifunctional-recombinant antibodies based on its Tribody technology. Such technology allows to engineer antibodies that bind to one, two or three targeted antigens. The company is also developing novel vaccination approaches based on the Extra Domain A from Fibronectin, an endogenous ligand for Toll-like Receptor 4, which is able to deliver antigens to TLR4-expressing dendritic cells (DCs) in vivo. Biotecnol is developing its pipeline before securing late-stage development and marketing partners
Company: Inimex Pharmaceuticals, Inc. Investor Relations Contact: John R. North, Ph.D. Investor Relations Contact Phone: 604-230-3501 Web: www.inimexpharma.com Date of Presentation: Thursday, April 7th, 2009 @ 11:30AM
Inimex Pharmaceuticals, Inc. is developing Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation. Inimex' first product, IMX942, will enter clinical trials in Q2, 2009.
IDR products have major market potential for infectious disease and inflammatory disorders. These products will significantly reduce morbidity and mortality in high risk patients in the hospital setting and in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization.
Company: Kalgene Pharma Inc Investor Relations Contact: J. Bacha Investor Relations Contact Phone: 604 317 7022 Web: www.kalgene.com Date of Presentation: Wednesday April 8, 2009
Kalgene Pharma Inc. was founded by in 2007 to commercialize a proven anti-cancer therapy. Kalgene’s first product, Immucothel, is an immunotherapy that has been approved for the treatment of bladder cancer by the Company’s partner in a number of international jurisdictions.
Kalgene has obtained the exclusive North American rights to Immocothel. Kalgene’s strategy is to rapidly commercialize Immucothel in North America for the treatment of superficial bladder carcinoma. Based on this first product, Kalgene plans to establish a portfolio of oncology and urology indications.
The Company has recruited an experienced management team and is undertaking a Series A financing.
Company: Madeira Therapeutics Investor Relations Contact: Pete Joiner Investor Relations Contact Phone: (913) 661-1962 Web: www.madeiratherapeutics.com Date of Presentation: April 9, 2009, at 10:15 am
Madeira Therapeutics, LLC, is a specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals that serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b)(2) approval method, which shortcuts the FDA approval by years, saving tens of millions of dollars in development costs. The company’s lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The second product is MT-003 for acute pain relief.
Company: Mithridion, Inc. Investor Relations Contact: Trevor M. Twose, CEO Investor Relations Contact Phone: 608-332-8319 Web: http://www.mithridion.com/ Date of Presentation: Wednesday April 8 at 4:30 PM
Mithridion, Inc. is a biopharmaceutical company that discovers and develops drugs for central nervous system (CNS) disorders, with an initial focus on Alzheimer’s disease (AD) and schizophrenia. Through its merger with Cognitive Pharmaceuticals Ltd. in June 2008, Mithridion is developing a pipeline of CNS drug candidates. MCD-386, the company’s lead candidate, a potential dual symptomatic and disease-modifying AD drug, is in Phase I clinical trials. Through Mithridion’s effective clinical execution, the company has advanced MCD-386 to initial clinical results within nine months of the merger with Cognitive. Mithridion has raised $7.4 million of angel and venture funding to date.
Company: Profectus BioSciences Investor Relations Contact: Shawn Patrick O'Brien, CEO Investor Relations Contact Phone: (443) 743 1106 Web: http://www.profectusbiosciences.com/ Date of Presentation: Thursday, April 9 2:00-2:15 PM.
Profectus Biosciences, is a research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Company’s first clinical vaccine candidate for human immunodeficiency virus (HIV) is planned to be tested in clinical trials in 2009. The Profectus proprietary vaccine design approach combines its rVSV and pDNA platforms via a unique prime boost strategy. Profectus broad pipeline will address (HIV), (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV). Profectus received over $36 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments.
Company: S.E.A. Medical Systems, Inc. Investor Relations Contact: Michael J. Weickert, Ph.D., CEO Investor Relations Contact Phone: 650-218-1840 Web: mweickert@seamedical.com Date of Presentation: Thursday, April 09, 2009
S.E.A. Medical Systems, Inc. of Sunnyvale California is a medical device company pioneering real-time advanced fluid sensing for medical applications. Each year, US hospital drug errors cause at least 7,000 deaths and 770,000 injuries costing $3.5B for hospitalization; most involve IV drugs. Our sterile, inexpensive, disposable sensor fits in the IV line and continuously detects and logs the drug and dose and reports instantly whenever either is unsafe. By integrating sensors, signal processing and wireless communication, our system prevents error from harming patients. This product can be on the market as early as 2011.ÿÿÿ
Company: Somnus Therapeutics, Inc Investor Relations Contact: Gary Cupit, CEO Web: gcupit@somnusthera.com Date of Presentation: April 9 - 11:45-11:58 AM
Somnus Therapeutics, Inc. (Bedminster, NJ) was founded in 2007 by Gary Cupit with Care Capital, a life sciences venture capital firm. In June 2007, Somnus signed an exclusive agreement with SkyePharma for worldwide development and commercialization of a controlled-release oral formulation of zaleplon, a non-benzodiazepine hypnotic agent, to address the major need of insomnia patients: preventing middle-of-the-night awakening without next-day hangover. SkyePharma has formulated and will manufacture SKP-1041 using their Geoclock™ technology. Somnus is applying technical advances in formulation, controlled-release, and clinical testing to speed clinical development and reduce costs. SKP-1041 will begin phase 2 studies in mid-2009.
About Business Wire
Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.
Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.
Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.
News 
Market Data 
Discover 
